Zobrazeno 1 - 10 of 10 pro vyhledávání: '"Jorge Soutric"'
1
[Untitled]
Autor: Juan Spatz, Norberto Caruso, Héctor Arenoso, Hugo Cohen Sabban, Ricardo M. Heguilén, Jorge Soutric
Publikováno v: International Journal of Pharmaceutical Medicine. 16:215-218
A rapid onset of drug action is desirable for patients experiencing panic attacks or episodes of acute anxiety. The aim of this single-dose, three-sequence, crossover study was to investigate the pharmacokinetics of the anxiolytic alprazolam after ad
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1fe7a24a21e6dbc68584a7ed5a209773
https://doi.org/10.1097/00124363-200210000-00003
Zobrazit plný text záznamu
2
A Pharmacodynamic Model to Support a 12-Hour Dosing Interval for Amoxicillin/Sulbactam, a Novel Oral Combination, in the Treatment of Community-Acquired Lower Respiratory Tract Infections
Autor: Jorgelina Smayevsky, L. Fernandez Canigia, A. Jasovich, F. Nicola, M. Blanco, M. Montoto, Hector J. Arenoso, C. Bantar, Jorge Soutric
Publikováno v: Journal of Chemotherapy. 12:223-227
We evaluated, by time-kill studies, the pharmacodynamics of amoxicillin/sulbactam (AMX/SUL, 875 mg/125 mg), a novel oral combination, against the major respiratory pathogens in 12 volunteers receiving a single dose. The sera corresponding to 50% of a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::599a37fcf94a19d9602b63b65793bd96
https://doi.org/10.1179/joc.2000.12.3.223
Zobrazit plný text záznamu
3
Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model
Autor: María Alejandra Berger, Liliana Fernández Canigia, Hector J. Arenoso, Carlos Bantar, Jorge Soutric
Publikováno v: Brazilian Journal of Infectious Diseases v.13 n.5 2009
Brazilian Journal of Infectious Diseases
Brazilian Society of Infectious Diseases (BSID)
instacron:BSID
Brazilian Journal of Infectious Diseases, Volume: 13, Issue: 5, Pages: 348-352, Published: OCT 2009
Brazilian Journal of Infectious Diseases, Vol 13, Iss 5, Pp 348-352
Amoxicillin-sulbactam (AMX-SUL) is an aminopenicillin/ss-lactamase inhibitor combination currently available in 29 countries and may be a suitable option for treating infections caused by Acinetobacter spp. Thus, we sought to search the optimal dosin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faab9fad2d073eae2c35e5fa136053a4
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702009000500006
Zobrazit plný text záznamu
4
Intravenous amoxicillin-sulbactam against Escherichia coli: optimizing the dose, component ratio and infusion time using a human pharmacodynamic model
Autor: L. Fernandez Canigia, María Alejandra Berger, Hector J. Arenoso, C. Bantar, Jorge Soutric
Publikováno v: Journal of chemotherapy (Florence, Italy). 21(3)
Amoxicillin-sulbactam (AMX-SUL) is an aminopenicillin/beta-lactamase inhibitor combination currently available in 29 countries which may be a suitable option for treating intra-abdominal infections. the aim of this study was to identify the optimal d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bb1b20426472da25ba5d32cd9ef21fd
https://pubmed.ncbi.nlm.nih.gov/19567350
Zobrazit plný text záznamu
5
Amoxicillin-sulbactam versus amoxicillin-clavulanic acid for the treatment of non-recurrent-acute otitis media in Argentinean children
Autor: Marcelo Marin, Daniel Stamboulian, Héctor Arenoso, Ricardo M. Heguilén, Maria T. Ishida, Victor Israele, Jorge Soutric, Andrés Sibbald, Javier M. Casellas
Publikováno v: International journal of pediatric otorhinolaryngology. 69(9)
Streptococcus pneumoniae (Sp) and Haemophilus influenzae (Hi) are the leading bacterial cause of acute otitis media (AOM), having the nasopharynx (NP) as their reservoir. In October 2001 we began a prospective, multicenter, randomized, evaluator blin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06667f495c2fcd9f5a0c2bd623af6deb
https://pubmed.ncbi.nlm.nih.gov/16061111
Zobrazit plný text záznamu
6
An ex-vivo pharmacodynamic study comparing bactericidal activity of amoxicillin/sulbactam, azithromycin, doxycycline and levofloxacin against Streptococcus pneumoniae
Autor: L. Fernandez Canigia, Hector J. Arenoso, C. Bantar, N. Caruso, Jorge Soutric, F. Nicola
Publikováno v: Journal of chemotherapy (Florence, Italy). 16(3)
We designed a 4-way crossover, ex-vivo pharmacodynamic study to compare the bactericidal rate of amoxicillin/sulbactam (AMX-SUL), azithromycin (AZM), doxycycline (DOX) and levofloxacin (LVX) against Streptococcus pneumoniae ATCC 49619. Six volunteers
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b464f0dc31d1cbf1b6a411aaefa794e8
https://pubmed.ncbi.nlm.nih.gov/15330320
Zobrazit plný text záznamu
7
Urine inhibitory titers against resistant Escherichia coli isolates after oral amoxicillin-sulbactam
Autor: José M, Casellas, Matías, Visser, Natalia, MacDougall, Gabriela, Tomé, Hugo Sabban, Cohen, Jorge, Soutric, Héctor, Arenoso
Publikováno v: Medicina. 63(3)
It has been previously shown that following the oral administration of amoxicillin-sulbactam (AXS) the urinary activity against Escherichia coli (Ec) is due to beta-lactamase inhibition (i.e. TEM-1) as well as to the intrinsic activity of sulbactam (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::51e9aef737f1bf5d899fdc95919276b5
https://pubmed.ncbi.nlm.nih.gov/12876904
Zobrazit plný text záznamu
8
Actividad in vitro de niveles séricos y urinarios de amoxicilina y amoxicilina-sulbactam sobre 820 cepas de Escherichia coli aisladas de infecciones urinarias bajas extrahospitalarias: Estudio sudamericano
Autor: Hugo Cohen S., Matías Visser, Natalia Mac Dougall, Héctor Arenoso, Jorge Soutric, Bárbara Coco, J. M. Casellas
Publikováno v: Revista chilena de infectología v.20 n.1 2003
SciELO Chile
CONICYT Chile
instacron:CONICYT
We previously showed urinary activity against Escherichia coli both after oral amoxicillin-sulbactam and sulbactam alone. A study was performed in 10 laboratories from 8 countries to determine the etiology of community acquired lower urinary tract in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::585cbbcc39d8faa3d866797614bc40d3
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182003000100002
Zobrazit plný text záznamu
9
Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms
Autor: M. Montoto, F. Nicola, A. Jasovich, Hector J. Arenoso, Jorgelina Smayevsky, Jorge Soutric, M. Blanco, L. Fernandez Canigia, C. Bantar
Publikováno v: Journal of chemotherapy (Florence, Italy). 13(4)
In order to establish a rationale for treating community-acquired lower respiratory tract infections, we assess here the pharmacodynamics of amoxicillin/sulbactam, 500mg/500mg, a formulation marketed in Argentina since 1988 and currently available in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c75d9b9960c66b513f0ad3f569c96fba
https://pubmed.ncbi.nlm.nih.gov/11589483
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje